drugset / Trial / NCT02104843

Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin

NCT02104843

Phase 1 Completed 18 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-label

Summary

The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 combination therapy on the exposure of Rosuvastatin.

Timeline

Start
2014-04
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Asunaprevir Small molecule Oral
Subject Beclabuvir Small molecule Oral
Subject Daclatasvir Small molecule Oral
Subject Rosuvastatin Small molecule Oral